PHAR vs. TRMD
PHAR (Pharming Group NV) and TRMD (TORM plc) are both stocks. PHAR operates in Biotechnology (Healthcare), while TRMD operates in Oil & Gas Midstream (Energy). Over the past 5 years, PHAR returned -0.13%/yr vs 42.68%/yr for TRMD. At a 0.06 correlation, their price movements are largely independent.
Performance
PHAR vs. TRMD - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, PHAR achieves a -30.73% return, which is significantly lower than TRMD's 51.10% return.
PHAR
- 1D
- -0.33%
- 1M
- -25.32%
- YTD
- -30.73%
- 6M
- -22.58%
- 1Y
- 8.95%
- 3Y*
- 0.27%
- 5Y*
- -0.13%
- 10Y*
- —
TRMD
- 1D
- 0.11%
- 1M
- -12.81%
- YTD
- 51.10%
- 6M
- 38.71%
- 1Y
- 87.62%
- 3Y*
- 18.91%
- 5Y*
- 42.68%
- 10Y*
- —
PHAR vs. TRMD - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|---|
PHAR Pharming Group NV | -30.73% | 75.56% | -11.94% | 3.63% | 23.38% | -41.16% | -9.01% |
TRMD TORM plc | 51.10% | 11.21% | -23.37% | 31.64% | 297.66% | 12.91% | -2.62% |
Correlation
The correlation between PHAR and TRMD is 0.09, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.09 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.06 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.06 |
Correlation (All Time) Calculated using the full available price history since Dec 24, 2020 | 0.06 |
Fundamentals
PHAR:
$858.52M
TRMD:
$2.91B
PHAR:
$75.89
TRMD:
$3.40
PHAR:
0.16
TRMD:
8.28
PHAR:
0.01
TRMD:
2.02
PHAR:
3.19
TRMD:
1.28
PHAR:
$106.76B
TRMD:
$1.41B
PHAR:
$85.64B
TRMD:
$575.03M
PHAR:
$6.24B
TRMD:
$639.99M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
PHAR vs. TRMD — Risk / Return Rank
PHAR
TRMD
PHAR vs. TRMD - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Pharming Group NV (PHAR) and TORM plc (TRMD). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| PHAR | TRMD | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -2.19 | ||
| Sortino ratioReturn per unit of downside risk | -2.21 | ||
| Omega ratioGain probability vs. loss probability | 1.09 | 1.35 | -0.25 |
| Calmar ratioReturn relative to maximum drawdown | 0.21 | 4.39 | -4.18 |
| Martin ratioReturn relative to average drawdown | 0.51 | 11.44 | -10.93 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| PHAR | TRMD | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 0.13 | 2.32 | -2.19 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | -0.00 | 0.93 | -0.94 |
Sharpe Ratio (All Time)Calculated using the full available price history | -0.08 | 0.48 | -0.56 |
Drawdowns
PHAR vs. TRMD - Drawdown Comparison
The maximum PHAR drawdown since its inception was -60.45%, roughly equal to the maximum TRMD drawdown of -60.59%. Use the drawdown chart below to compare losses from any high point for PHAR and TRMD.
Loading charts...
Drawdown Indicators
| PHAR | TRMD | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -60.45% | -60.59% | +0.14% |
Max Drawdown (1Y)Largest decline over 1 year | -43.34% | -20.06% | -23.28% |
Max Drawdown (3Y)Largest decline over 3 years | -57.32% | -60.59% | +3.27% |
Max Drawdown (5Y)Largest decline over 5 years | -57.32% | -60.59% | +3.27% |
Current DrawdownCurrent decline from peak | -42.21% | -17.33% | -24.88% |
Average DrawdownAverage peak-to-trough decline | -34.20% | -22.58% | -11.62% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 17.74% | 7.69% | +10.05% |
Volatility
PHAR vs. TRMD - Volatility Comparison
Pharming Group NV (PHAR) has a higher volatility of 35.05% compared to TORM plc (TRMD) at 14.52%. This indicates that PHAR's price experiences larger fluctuations and is considered to be riskier than TRMD based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| PHAR | TRMD | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 35.05% | 14.52% | +20.53% |
Volatility (6M)Calculated over the trailing 6-month period | 51.16% | 27.84% | +23.32% |
Volatility (1Y)Calculated over the trailing 1-year period | 71.75% | 38.07% | +33.68% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 70.15% | 46.00% | +24.15% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 68.23% | 59.90% | +8.33% |
Dividends
PHAR vs. TRMD - Dividend Comparison
PHAR has not paid dividends to shareholders, while TRMD's dividend yield for the trailing twelve months is around 8.59%.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
PHAR Pharming Group NV | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
TRMD TORM plc | 8.59% | 10.32% | 30.13% | 23.05% | 6.99% | 0.00% | 14.89% |
Financials
PHAR vs. TRMD - Financials Comparison
This section allows you to compare key financial metrics between Pharming Group NV and TORM plc. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
PHAR vs. TRMD - Profitability Comparison
PHAR - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Pharming Group NV reported a gross profit of 66.04M and revenue of 72.71M. Therefore, the gross margin over that period was 90.8%.
TRMD - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, TORM plc reported a gross profit of 157.74M and revenue of 395.84M. Therefore, the gross margin over that period was 39.9%.
PHAR - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Pharming Group NV reported an operating income of 2.52M and revenue of 72.71M, resulting in an operating margin of 3.5%.
TRMD - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, TORM plc reported an operating income of 135.10M and revenue of 395.84M, resulting in an operating margin of 34.1%.
PHAR - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Pharming Group NV reported a net income of -5.23M and revenue of 72.71M, resulting in a net margin of -7.2%.
TRMD - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, TORM plc reported a net income of 120.52M and revenue of 395.84M, resulting in a net margin of 30.5%.
Frequently Asked Questions
PHAR and TRMD have a correlation of 0.09, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
PHAR has higher volatility (35.05%) compared to TRMD (14.52%). In terms of maximum drawdown, PHAR dropped -60.45% vs TRMD's -60.59%.
TRMD currently has the higher Sharpe Ratio (2.32 vs 0.13), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for PHAR and TRMD
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer